A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis

166Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Antiphospholipid syndrome (APS) is a clinical autoimmune disorder characterized by thrombosis/pregnancy morbidity associated with the persistence of lupus anticoagulant (LA) and/or anticardiolipin (aCL) antibodies. We assessed the contribution of antibodies to β2-glycoprotein I (anti-β2GPI) and prothrombin (anti-PT) to the thrombotic risk in a cohort of 194 consecutive patients with persistent LA and/or aCL. Median follow-up was 45 months. A total of 39 patients (20.1%) had one documented episode of thrombosis during follow-up. Eleven of these patients had no previous thrombosis before enrollment in the study and 28 had recurrences of thrombosis. There were 21 venous and 18 arterial thrombotic events and the overall incidence of thrombosis was 5.6% per patient-year. After multivariate analysis, the male sex (P = 0.025), a previous thrombosis (P < 0.01), the presence of anti-β2GPI (P = 0.001), and the presence of anti-PT (P = 0.03) remained as independent risk factors for recurrent thrombosis. Only IgG anti-β2GPI and anti-PT were associated with an increased risk of thrombosis (P < 0.01 and P = 0.005). Patients testing positive for anti-β2GPI had a higher rate of thrombosis than did antiphospholipid patients without anti-β2GPI (8.0% vs. 3.1% per patient-year). Similarly, a higher rate of thrombosis was found in patients with positive anti-PT compared with patients without anti-PT (8.6% vs. 3.5% per patient-year). Considering only the group of 142 LA positive patients, the highest incidence of thrombosis was found in LA patients positive for both anti-β2GPI and anti-PT (8.4% per patient-year). In conclusion, the presence of IgG anti-β2GPI and anti-PT in patients with LA and/or aCL and mainly in those with LA predicts a higher risk of thromboembolic events. © 2005 International Society on Thrombosis and Haemostasis.

References Powered by Scopus

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International Workshop

2548Citations
N/AReaders
Get full text

Criteria for the diagnosis of lupus anticoagulants: An update

1332Citations
N/AReaders
Get full text

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature

896Citations
N/AReaders
Get full text

Cited by Powered by Scopus

EULAR recommendations for the management of antiphospholipid syndrome in adults

798Citations
N/AReaders
Get full text

Antiphospholipid syndrome

731Citations
N/AReaders
Get full text

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies

422Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Forastiero, R., Martinuzzo, M., Pombo, G., Puente, D., Rossi, A., Celebrin, L., … Forastiero, R. R. (2005). A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis. Journal of Thrombosis and Haemostasis, 3(6), 1231–1238. https://doi.org/10.1111/j.1538-7836.2005.01295.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

50%

Researcher 9

28%

Professor / Associate Prof. 6

19%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 27

75%

Biochemistry, Genetics and Molecular Bi... 4

11%

Agricultural and Biological Sciences 3

8%

Social Sciences 2

6%

Save time finding and organizing research with Mendeley

Sign up for free